Vom Impfstoff-Superstar zum Ärgernis: Die schwierige Suche nach der Zukunft von Biontech
Das Mainzer Unternehmen schliesst drei Standorte in Deutschland, für die es keinen Käufer gefunden hat. Es konzentriert sich nun voll auf Medikamente gegen Krebs. Der neue Weg ist voller Hindernisse.
Biontech, the German company behind the first Covid-19 vaccine, is facing a difficult transition as it shuts down locations in Germany that were used to produce coronavirus vaccines. The company has not found any buyers for three sites, and is now focusing on cancer medications. This move has been met with disappointment by local officials in Mainz, Tübingen, Marburg, and Idar-Oberstein, who emphasized the importance of preserving highly skilled jobs and the decades-long biotechnology location.
Boris Palmer, the mayor of Tübingen, expressed that the decision was "shocking" and "unjustifiable". Biontech's CEO, Guido Oelkers, will now lead the company as it navigates a challenging restructuring period. The company's revenue dropped almost in half to 233 million euros last year, and its net loss increased significantly to nearly 1.4 billion euros.
Despite this, Biontech remains optimistic about its future, particularly in the development of cancer medications. The company is investing heavily in this area, with several cancer-related treatments currently in clinical trials. However, the competition for these projects is fierce, as evidenced by Moderna's recent success in developing a black skin cancer therapy.
Despite the challenges, analysts and investors remain cautiously optimistic about Biontech's prospects, citing the company's strong foundation in research and successful businesses.
Written by urgent.news from NZZ Wirtschaft's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
